Temporal Concept
Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study
Lp(a ), RNA, Small Interfering, Cardiovascular Diseases
iOnctura Secures €80 Million in Series B Financing to Advance Rare Eye Cancer Treatment
iOnctura, Series B financing, rare eye cancer, uveal melanoma, roginolisib, cancer treatment
Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC
Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion
Takeda’s Soticlestat Misses Main Goal in Two Pivotal Epilepsy Studies
Soticlestat, Takeda, Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Phase 3 Trials, Seizure Frequency
Huntington’s Disease Clinical Trials: Updates on Dalzanemdor and Tominersen
Huntington’s disease, clinical trials, dalzanemdor, tominersen, cognitive impairment, RNA-based therapy, NMDA receptor modulator, Phase 2 and Phase 3 studies
Eisai Seeks FDA Approval for Monthly IV Dosing of LEQEMBI for Alzheimer’s Disease Treatment
LEQEMBI, Eisai, FDA, Alzheimer’s disease, monthly IV dosing, subcutaneous autoinjector, lecanemab-irmb, Biogen
Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance
Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance
Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor
Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology
Amgen’s Uplizna Achieves Phase 3 Success in Treating Immunoglobulin G4-Related Disease, Paving Way for Label Expansion
Amgen, Uplizna, Phase 3, Immunoglobulin G4-Related Disease, IgG4-RD, Rare Autoimmune Disease, Label Expansion
Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda
Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program